Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

9 treatments under study, led by 09 Nacl Isotonic Saline Solution

Research Leaders

5 sponsors active, led by University of Kentucky

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (3)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT07534280Not ApplicableCompletedPrimary

Herbal Tea Extract for Management of Rhinosinusitis

NCT05984004Not ApplicableCompletedPrimary

Safety Evaluation of Intranasal Use of DSM 32444 Postbiotic in Humans

NCT03068728Not ApplicableCompletedPrimary

Analysis of Hemostatic Agents Compared to Physiologic Hemostasis

Showing all 3 trials

Research Network

Common Treatments

  • 09 Nacl Isotonic Saline Solution1
  • Nasopore1
  • Bacillus Subtilis Dsm32444 Inactivated1
  • Nasal Saline1
  • Amoxicillin Clavulanates1

Active Sponsors

  • University of Kentucky1
  • Thai Binh University of Medicine and Pharmacy1
  • Deraya University1
  • Huro Biotech Joint Stock Company1
  • St. Louis University1

Top Investigators

Activity Timeline